Q3 2023 EPS Estimates for Viking Therapeutics, Inc. (NASDAQ:VKTX) Increased by Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) – Research analysts at William Blair lifted their Q3 2023 earnings per share (EPS) estimates for Viking Therapeutics in a report issued on Wednesday, February 8th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings per share of ($0.22) for the quarter, up from their previous forecast of ($0.23). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.93) per share. William Blair also issued estimates for Viking Therapeutics’ Q4 2023 earnings at ($0.22) EPS, FY2023 earnings at ($0.89) EPS and FY2024 earnings at ($0.91) EPS.

Several other brokerages have also recently issued reports on VKTX. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Viking Therapeutics in a research report on Thursday, February 9th. Maxim Group boosted their price target on shares of Viking Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, December 19th. Oppenheimer decreased their target price on Viking Therapeutics to $10.00 in a report on Tuesday, November 1st. StockNews.com downgraded Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 9th. Finally, Raymond James lifted their price objective on Viking Therapeutics from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, February 9th.

Viking Therapeutics Trading Down 0.4 %

VKTX opened at $10.63 on Monday. The stock’s 50-day moving average price is $7.92 and its 200 day moving average price is $5.07. Viking Therapeutics has a 12-month low of $2.02 and a 12-month high of $11.15. The firm has a market cap of $815.21 million, a price-to-earnings ratio of -11.68 and a beta of 0.77.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VKTX. Laurion Capital Management LP acquired a new stake in Viking Therapeutics during the second quarter worth approximately $3,826,000. Cornerstone Capital Inc. grew its holdings in shares of Viking Therapeutics by 3.5% during the third quarter. Cornerstone Capital Inc. now owns 143,980 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 4,840 shares during the last quarter. PVG Asset Management Corp acquired a new stake in shares of Viking Therapeutics during the third quarter worth about $40,000. CSS LLC IL lifted its holdings in shares of Viking Therapeutics by 190.9% in the 2nd quarter. CSS LLC IL now owns 29,258 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 19,200 shares during the last quarter. Finally, Quantum Private Wealth LLC boosted its position in shares of Viking Therapeutics by 8.8% in the 2nd quarter. Quantum Private Wealth LLC now owns 50,548 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 4,100 shares during the period. Hedge funds and other institutional investors own 34.71% of the company’s stock.

About Viking Therapeutics

(Get Rating)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm’s clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214.

Featured Articles

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Viking Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *